Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sutro Biopharma (STRO) Revenue (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Revenue for 9 consecutive years, with $6.6 million as the latest value for Q4 2025.

  • Quarterly Revenue fell 55.43% to $6.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $85.7 million through Dec 2025, up 58.37% year-over-year, with the annual reading at $102.5 million for FY2025, 65.18% up from the prior year.
  • Revenue hit $6.6 million in Q4 2025 for Sutro Biopharma, down from $9.7 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $113.7 million in Q4 2023 to a low of $5.7 million in Q1 2025.
  • Historically, Revenue has averaged $21.2 million across 5 years, with a median of $12.8 million in 2023.
  • Biggest five-year swings in Revenue: surged 1217.44% in 2023 and later crashed 86.98% in 2024.
  • Year by year, Revenue stood at $10.7 million in 2021, then dropped by 18.98% to $8.6 million in 2022, then soared by 1217.44% to $113.7 million in 2023, then plummeted by 86.98% to $14.8 million in 2024, then plummeted by 55.43% to $6.6 million in 2025.
  • Business Quant data shows Revenue for STRO at $6.6 million in Q4 2025, $9.7 million in Q3 2025, and $63.7 million in Q2 2025.